Correct Answer: B. Gestational diabetes
Gestational diabetes mellitus (GDM) is a metabolic complication that develops during pregnancy in women without pre-existing diabetes. The key discriminator here is that GDM is an antenatal complication of pregnancy itself, not a teratogenic drug exposure. The question stem specifies "the first baby (the second baby given as reference is a normal newborn)"—this phrasing indicates the second pregnancy was uncomplicated, making GDM the expected antenatal complication in the first pregnancy. GDM occurs in 3–5% of Indian pregnancies (higher in urban populations) and is diagnosed by oral glucose tolerance testing (75 g OGTT) between 24–28 weeks. It increases maternal risks of preeclampsia, polyhydramnios, and operative delivery, while fetal risks include macrosomia, neonatal hypoglycemia, and birth trauma. Unlike teratogenic drugs (phenytoin, valproate, ACE inhibitors), GDM is a metabolic derangement of pregnancy that can recur or persist in subsequent pregnancies if not managed. The normal second baby rules out inherited genetic conditions or chronic maternal disease; GDM fits the pattern of a pregnancy-specific complication that may or may not recur depending on maternal factors and weight gain in the second pregnancy.
Why the other options are wrong
A. Intake of Phenytoin — Phenytoin is a teratogenic drug (Fetal Hydantoin Syndrome: cleft palate, cardiac defects, growth restriction), not an antenatal complication of pregnancy. If the mother took phenytoin in the first pregnancy, the first baby would show congenital anomalies, not the mother an antenatal complication. The second baby being normal suggests no chronic maternal disease requiring phenytoin. This is a drug exposure, not a pregnancy complication. C. Intake of sodium valproate — Sodium valproate is a highly teratogenic antiepileptic (neural tube defects, developmental delay, cardiac anomalies—Fetal Valproate Syndrome). Like phenytoin, it is a drug exposure causing fetal harm, not a maternal antenatal complication. The normal second baby rules out chronic epilepsy requiring valproate. This confuses drug teratogenicity with pregnancy complications. D. Intake of ACE inhibitors — ACE inhibitors cause fetal renal dysgenesis, oligohydramnios, and fetal death when used in second/third trimester (ACE inhibitor fetopathy), not maternal antenatal complications. They are contraindicated in pregnancy due to teratogenicity. A normal second baby argues against chronic hypertension requiring ACE inhibitors. This is a drug-induced fetal complication, not a pregnancy-related maternal metabolic disorder.
High-Yield Facts
- GDM is a pregnancy-induced metabolic disorder (not teratogenic), diagnosed by 75 g OGTT at 24–28 weeks in India per ICMR guidelines.
- Teratogenic drugs (phenytoin, valproate, ACE inhibitors) cause fetal congenital anomalies, not maternal antenatal complications.
- Fetal Hydantoin Syndrome: cleft palate, cardiac defects, growth restriction, developmental delay from phenytoin exposure.
- Fetal Valproate Syndrome: neural tube defects (spina bifida), cardiac anomalies, developmental delay—highest teratogenic risk among anticonvulsants.
- ACE inhibitor fetopathy: renal dysgenesis, oligohydramnios, fetal death in 2nd/3rd trimester; contraindicated in pregnancy.
- GDM increases maternal risks: preeclampsia, polyhydramnios, operative delivery; fetal risks: macrosomia, neonatal hypoglycemia, birth trauma.
Mnemonics
TERATOGENIC DRUGS in Pregnancy ACE-VPS: ACE inhibitors, Valproate, Phenytoin, Statins—all cause fetal anomalies, not maternal complications. Use when distinguishing drug teratogenicity from pregnancy disorders. GDM vs. Drug Teratogenicity GDM = Maternal Metabolic; Drugs = Fetal Structural. GDM affects mother's glucose metabolism and increases maternal complications (preeclampsia, polyhydramnios). Teratogenic drugs cause fetal birth defects. When question asks 'maternal antenatal complication,' think GDM.
NBE Trap
NBE pairs teratogenic drug exposures (phenytoin, valproate, ACE inhibitors) with the term "antenatal complications" to trap students who conflate drug-induced fetal anomalies with pregnancy-related maternal complications. The key is recognizing that GDM is a maternal metabolic disorder of pregnancy, while the drugs listed cause fetal structural defects—fundamentally different categories.
Clinical Pearl
In Indian obstetric practice, GDM screening at 24–28 weeks (75 g OGTT) is now standard per ICMR guidelines. A mother with GDM in the first pregnancy has a 50–60% recurrence risk in the second pregnancy if weight gain and lifestyle are not controlled—explaining why the second baby may be normal (if GDM was prevented) or why GDM recurs. This distinguishes GDM from teratogenic drug effects, which would affect the first baby's anatomy regardless of the second pregnancy.
_Reference: DC Dutta's Textbook of Obstetrics (8th ed.), Ch. 23 (Gestational Diabetes); Harrison's Principles of Internal Medicine, Ch. 296 (Diabetes Mellitus); ICMR Guidelines on GDM (2018)_